Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Reiter, Andreas [VerfasserIn]   i
 Schwaab, Juliana [VerfasserIn]   i
 DeAngelo, Daniel J. [VerfasserIn]   i
 Gotlib, Jason [VerfasserIn]   i
 Deininger, Michael W. [VerfasserIn]   i
 Pettit, Kristen M. [VerfasserIn]   i
 Alvarez-Twose, Iván [VerfasserIn]   i
 Vannucchi, Alessandro M. [VerfasserIn]   i
 Panse, Jens [VerfasserIn]   i
 Platzbecker, Uwe [VerfasserIn]   i
 Hermine, Olivier [VerfasserIn]   i
 Dybedal, Ingunn [VerfasserIn]   i
 Lin, Hui-Min [VerfasserIn]   i
 Rylova, Svetlana N. [VerfasserIn]   i
 Ehlert, Katrin [VerfasserIn]   i
 Dimitrijević, Saša [VerfasserIn]   i
 Radia, Deepti H. [VerfasserIn]   i
Titel:Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
Verf.angabe:Andreas Reiter, Juliana Schwaab, Daniel J. DeAngelo, Jason Gotlib, Michael W. Deininger, Kristen M. Pettit, Iván Alvarez-Twose, Alessandro M. Vannucchi, Jens Panse, Uwe Platzbecker, Olivier Hermine, Ingunn Dybedal, Hui-Min Lin, Svetlana N. Rylova, Katrin Ehlert, Saša Dimitrijević, and Deepti H. Radia, on behalf of the EXPLORER and PATHFINDER study investigators
E-Jahr:2022
Jahr:November 8, 2022
Umfang:13 S.
Fussnoten:Gesehen am 24.07.2023
Titel Quelle:Enthalten in: Blood advances
Ort Quelle:Washington, DC : American Society of Hematology, 2016
Jahr Quelle:2022
Band/Heft Quelle:6(2022), 21 vom: Nov., Seite 5750-5762
ISSN Quelle:2473-9537
Abstract:Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm, driven by the KIT D816V mutation in >90% of patients. Avapritinib, a potent, highly selective D816V-mutant KIT inhibitor, is approved for treatment of adults with AdvSM by the US Food and Drug Administration, regardless of prior therapy, and the European Medicines Agency for patients with prior systemic therapy, based on EXPLORER (#NCT02561988; clinicaltrials.gov) and PATHFINDER (#NCT03580655; clinicaltrials.gov) clinical studies. We present latest pooled efficacy and safety analyses from patients who received ≥1 systemic therapy prior to avapritinib in EXPLORER/PATHFINDER. Overall response rate in response-evaluable patients (n = 31) was 71% (95% confidence interval: 52% to 86%; 22/31), including 19% (6/31) with complete remission (CR)/CR with partial recovery of peripheral blood counts (CRh). Median time to response was 2.3 months, median time to CR/CRh was 7.4 months, and median duration of response (DOR) was not reached. Reductions ≥50% in bone marrow mast cell infiltration (89%), KIT D816V variant allele fraction (66%), serum tryptase (89%), and reductions ≥35% in spleen size (70%) occurred in most patients. Median OS was not reached (median follow-up 17.7 months). Avapritinib was effective in all AdvSM subtypes, regardless of number/type of prior therapies or poor prognostic somatic mutations. Treatment-related adverse events (TRAEs) were observed in 94% of patients, most commonly grade 1/2; 57% had TRAEs of at least grade 3; 81% remained on treatment at 6 months. Avapritinib in adults with AdvSM who received prior systemic therapy was generally well tolerated, with high response rates regardless of prior systemic therapy.
DOI:doi:10.1182/bloodadvances.2022007539
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.1182/bloodadvances.2022007539
 kostenfrei: Volltext: https://ashpublications.org/bloodadvances/article/6/21/5750/485432/Efficacy-and-safety-of-avapritinib-in-previously
 DOI: https://doi.org/10.1182/bloodadvances.2022007539
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:185350193X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69100585   QR-Code
zum Seitenanfang